Status:
COMPLETED
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
Lead Sponsor:
Novartis
Conditions:
Heterozygous Familial Hypercholesterolemia
Mixed Dyslipidemia
Eligibility:
All Genders
10-16 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to assess the safety and efficacy of fluvastatin in children diagnosed with heterozygous familial hypercholesterolemia
Eligibility Criteria
Inclusion
- 10-16 years old Heterozygous familial hypercholesterolemia
Exclusion
- Homozygous familial hypercholesterolemia Pregnant or lactating females Major surgery during the six month prior study
- Other protocol defined inclusion and exclusion criteria may apply
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00171236
Start Date
October 1 2001
End Date
March 1 2005
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Basel, Switzerland